{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:40:23Z","timestamp":1787017223953,"version":"build-2736575974"},"reference-count":40,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["JR24\/00008"],"award-info":[{"award-number":["JR24\/00008"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH-1U01NS120885"],"award-info":[{"award-number":["NIH-1U01NS120885"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-LABX-0042"],"award-info":[{"award-number":["ANR-11-LABX-0042"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-18-RHUS-0012"],"award-info":[{"award-number":["ANR-18-RHUS-0012"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Neurol Neurosurg Psychiatry"],"accepted":{"date-parts":[[2025,9,17]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Patients with leucine-rich glioma-inactivated 1 antibody (LGI1-Ab) encephalitis are typically elderly men that often carry human leucocyte antigen (HLA)-\n                      <jats:italic>DRB1*07:01<\/jats:italic>\n                      (\u224890%). Herein, we aimed to investigate whether patients with atypical demographic profiles or not carrying\n                      <jats:italic>DRB1*07:01<\/jats:italic>\n                      have distinct clinical manifestations and outcome.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective chart review of LGI1-Ab patients diagnosed at the French Reference Centre and three other European centres.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among 238 patients included, median age at onset was 66 years (IQR: 60\u201373), 65% were male, 89% carried\n                      <jats:italic>DRB1*07:01<\/jats:italic>\n                      and 10%\n                      <jats:italic>DRB1*04:02<\/jats:italic>\n                      , another known secondary HLA association. We identified three age groups (young, typical, old) based on percentiles of age distribution. Young (\u226451 years) patients were less commonly male (35%, p=0.004), while faciobrachial dystonic seizures (FBDS; 65%, p=0.047) and hyponatraemia (64%, p=0.046) were more frequent in old (\u226579 years) patients. Old patients experienced poor outcome (modified Rankin Scale [mRS] &gt;2 at last follow-up) more frequently (64%, p&lt;0.001). There were no significant differences between males and females.\n                      <jats:italic>DRB1*07:01<\/jats:italic>\n                      non-carriers were younger (p=0.005) and less frequently male (47%, p=0.044), while non-carriers of both\n                      <jats:italic>DRB1*07:01<\/jats:italic>\n                      and\n                      <jats:italic>DRB1*04:02<\/jats:italic>\n                      experienced poor outcome more commonly (64%, p=0.005). Older age (adjusted OR: 1.08, 95%\u2009CI [1.02 to 1.14], p=0.008), higher mRS at nadir (4.22 [2.46\u20137.24], p&lt;0.001) and\n                      <jats:italic>DRB1*07:01<\/jats:italic>\n                      non-carrier status (8.39 [1.88\u201337.44], p=0.005) were independently associated with poor outcome. Moreover, older age (1.08 [1.04\u20131.11], p&lt;0.001), FBDS (2.20 [1.17\u20134.13], p=0.014) and hyponatraemia (2.30 [1.22\u20134.34], p=0.010) were associated with severe encephalitis (mRS &gt;3 at nadir).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Age appears to be the main driver of clinical presentation, severity and outcome in LGI1-Ab encephalitis. Remarkably,\n                      <jats:italic>DRB1*07:01<\/jats:italic>\n                      non-carriers are younger, more commonly female and experience poorer prognosis, reflecting a distinct pathophysiology.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/jnnp-2025-335960","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T17:20:40Z","timestamp":1760548840000},"page":"71-80","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical specificities and outcome of LGI1-antibody encephalitis according to age, sex and HLA"],"prefix":"10.1136","volume":"97","clinical-trial-number":[{"clinical-trial-number":"nct04823728","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04823728","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3415-6428","authenticated-orcid":false,"given":"Lucia","family":"Campetella","sequence":"first","affiliation":[{"name":"French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, 69500 Bron, France"},{"name":"Neurology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9236-2428","authenticated-orcid":false,"given":"Macarena","family":"Villagr\u00e1n-Garc\u00eda","sequence":"additional","affiliation":[{"name":"French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, 69500 Bron, France"},{"name":"MeLiS \u2013 UCBL-CNRS UMR 5284 \u2013 INSERM U1314, Universite Claude Bernard Lyon 1, 69008 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5551-0185","authenticated-orcid":false,"given":"Antonio","family":"Farina","sequence":"additional","affiliation":[{"name":"French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, 69500 Bron, France"},{"name":"MeLiS \u2013 UCBL-CNRS UMR 5284 \u2013 INSERM U1314, Universite Claude Bernard Lyon 1, 69008 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Villard","sequence":"additional","affiliation":[{"name":"French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, 69500 Bron, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Benaiteau","sequence":"additional","affiliation":[{"name":"French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, 69500 Bron, France"},{"name":"MeLiS \u2013 UCBL-CNRS UMR 5284 \u2013 INSERM U1314, Universite Claude Bernard Lyon 1, 69008 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3652-7061","authenticated-orcid":false,"given":"Alberto","family":"Vogrig","sequence":"additional","affiliation":[{"name":"Clinical Neurology, Department of Head-Neck and Neuroscience, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), 33100 Udine, Italy"},{"name":"Department of Medicine (DMED), University of Udine, 33100 Udine, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6270-0956","authenticated-orcid":false,"given":"Raffaele","family":"Iorio","sequence":"additional","affiliation":[{"name":"Neuroscience Department, Catholic University of the Sacred Heart, 00168 Rome, Italy"},{"name":"Clinical Neurology, Department of Ageing, Neurosciences, Head-neck and Orthopaedics Sciences, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00e1s Lundahl","family":"Ciano-Petersen","sequence":"additional","affiliation":[{"name":"Neurology Service, Regional University Hospital of M\u00e1laga, 29010 M\u00e1laga, Spain"},{"name":"Biomedical Research Institute of M\u00e1laga and Nanomedicine Platform-IBIMA Platform BIONAND, 29590 M\u00e1laga, Spain"},{"name":"Andalusian Network for Clinical and Translational Research in Neurology (NeuroRECA), 29010 M\u00e1laga, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Psimaras","sequence":"additional","affiliation":[{"name":"Neurology Department 2-Mazarin, H\u00f4pitaux Universitaires La Piti\u00e9 Salp\u00eatri\u00e8re-Charles Foix, APHP, 75013 Paris, France"},{"name":"Paris Brain Institute, ICM, INSERM, CNRS, Sorbonne Universit\u00e9, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0077-8114","authenticated-orcid":false,"given":"Vincent","family":"Navarro","sequence":"additional","affiliation":[{"name":"Paris Brain Institute, ICM, INSERM, CNRS, Sorbonne Universit\u00e9, 75013 Paris, France"},{"name":"APHP, Epilepsy Unit, Reference Centre of Rare epilepsies, ERN-EPICARE, Piti\u00e9-Salp\u00eatri\u00e8re Hospital, 75013 Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente Peris","family":"Sempere","sequence":"additional","affiliation":[{"name":"Stanford Centre for Sleep Science and Medicine, Stanford University, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gon\u00e7alves","sequence":"additional","affiliation":[{"name":"Immunology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69495 Oullins-Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Picard","sequence":"additional","affiliation":[{"name":"French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, 69500 Bron, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Rogemond","sequence":"additional","affiliation":[{"name":"French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, 69500 Bron, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-3056","authenticated-orcid":false,"given":"Bastien","family":"Joubert","sequence":"additional","affiliation":[{"name":"French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, 69500 Bron, France"},{"name":"Neurology Department, Centre Hospitalier Lyon Sud, Hospices Civils de Lyon, 69495 Oullins-Pierre-B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Mignot","sequence":"additional","affiliation":[{"name":"Stanford Centre for Sleep Science and Medicine, Stanford University, Palo Alto, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4721-5952","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Honnorat","sequence":"additional","affiliation":[{"name":"French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, 69500 Bron, France"},{"name":"MeLiS \u2013 UCBL-CNRS UMR 5284 \u2013 INSERM U1314, Universite Claude Bernard Lyon 1, 69008 Lyon, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5958-3288","authenticated-orcid":false,"given":"Sergio","family":"Mu\u00f1iz-Castrillo","sequence":"additional","affiliation":[{"name":"French National Reference Center for Paraneoplastic Neurological Syndromes and Autoimmune Encephalitis, Hospices Civils de Lyon, 69500 Bron, France"},{"name":"Neurology Department, Hospital Universitario 12 de Octubre, Instituto de Investigaci\u00f3n Sanitaria Hospital 12 de Octubre (imas12), 28041 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"2025121202251622000_97.1.71.1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24979"},{"key":"2025121202251622000_97.1.71.2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1212\/WNL.0000000000003173","article-title":"Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up","volume":"87","author":"van Sonderen","year":"2016","journal-title":"Neurology (ECronicon)"},{"key":"2025121202251622000_97.1.71.3","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1212\/WNL.0000000000003009","article-title":"Anti-LGI1-associated cognitive impairment: Presentation and long-term outcome","volume":"87","author":"Arino","year":"2016","journal-title":"Neurology Aug"},{"key":"2025121202251622000_97.1.71.4","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1093\/brain\/awy109","article-title":"Distinct HLA associations of LGI1 and CASPR2-antibody diseases","volume":"141","author":"Binks","year":"2018","journal-title":"Brain (Bacau)"},{"key":"2025121202251622000_97.1.71.5","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000974","article-title":"Clinical and Prognostic Value of Immunogenetic Characteristics in Anti-LGI1 Encephalitis","volume":"8","author":"Mu\u00f1iz-Castrillo","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025121202251622000_97.1.71.6","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000001140","article-title":"Human Leukocyte Antigen Association Study Reveals DRB1*04:02 Effects Additional to DRB1*07:01 in Anti-LGI1 Encephalitis","volume":"9","author":"Peris Sempere","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025121202251622000_97.1.71.7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24858"},{"key":"2025121202251622000_97.1.71.8","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24860"},{"key":"2025121202251622000_97.1.71.9","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200103","article-title":"New Insights on DR and DQ Human Leukocyte Antigens in Anti-LGI1 Encephalitis","volume":"10","author":"Segal","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025121202251622000_97.1.71.10","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1111\/ene.15376","article-title":"HLA-DRB1*03:01 is associated with female sex and younger age of anti-LGI1 encephalitis","volume":"29","author":"Liu","year":"2022","journal-title":"Eur J Neurol"},{"key":"2025121202251622000_97.1.71.11","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/jamaneurol.2021.0477","article-title":"Residual Fatigue and Cognitive Deficits in Patients After Leucine-Rich Glioma-Inactivated 1 Antibody Encephalitis","volume":"78","author":"Binks","year":"2021","journal-title":"JAMA Neurol"},{"key":"2025121202251622000_97.1.71.12","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000652","article-title":"Telemedicine assessment of long-term cognitive and functional status in anti-leucine-rich, glioma-inactivated 1 encephalitis","volume":"7","author":"Sola-Valls","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025121202251622000_97.1.71.13","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200228","article-title":"Predictors and Clinical Characteristics of Relapses in LGI1-Antibody Encephalitis","volume":"11","author":"Campetella","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025121202251622000_97.1.71.14","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/brain\/awx323","article-title":"The importance of early immunotherapy in patients with faciobrachial dystonic seizures","volume":"141","author":"Thompson","year":"2018","journal-title":"Brain (Bacau)"},{"key":"2025121202251622000_97.1.71.15","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1001\/jamaneurol.2016.4226","article-title":"Evaluation of Cognitive Deficits and Structural Hippocampal Damage in Encephalitis With Leucine-Rich, Glioma-Inactivated 1 Antibodies","volume":"74","author":"Finke","year":"2017","journal-title":"JAMA Neurol"},{"key":"2025121202251622000_97.1.71.16","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1093\/brain\/aww012","article-title":"Motor cortex and hippocampus are the two main cortical targets in LGI1-antibody encephalitis","volume":"139","author":"Navarro","year":"2016","journal-title":"Brain (Bacau)"},{"key":"2025121202251622000_97.1.71.17","doi-asserted-by":"crossref","first-page":"578346","DOI":"10.1016\/j.jneuroim.2024.578346","article-title":"Corticospinal tract hyperintensity in patients with LGI1-antibody encephalitis and other central nervous system disorders with neuroglial antibodies","volume":"390","author":"Campetella","year":"2024","journal-title":"J Neuroimmunol"},{"key":"2025121202251622000_97.1.71.18","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22307"},{"key":"2025121202251622000_97.1.71.19","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200178","article-title":"Clinical Determinants of Longitudinal Disability in LGI-1-IgG Autoimmune Encephalitis","volume":"11","author":"Aboseif","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025121202251622000_97.1.71.20","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-327302"},{"key":"2025121202251622000_97.1.71.21","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200034","article-title":"Seizure Semiology in Antibody-Associated Autoimmune Encephalitis","volume":"9","author":"Kaaden","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025121202251622000_97.1.71.22","first-page":"e1141","article-title":"Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis","volume":"97","author":"Smith","year":"2021","journal-title":"Neurology (ECronicon)"},{"key":"2025121202251622000_97.1.71.23","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3506-13.2013"},{"key":"2025121202251622000_97.1.71.24","doi-asserted-by":"publisher","DOI":"10.1016\/J.NEUROIMAGE.2018.11.008"},{"key":"2025121202251622000_97.1.71.25","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200155","article-title":"Electrolyte Imbalance in Anti-LGI1 Encephalitis: It Is Not All in Your Head","volume":"10","author":"Gadoth","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2025121202251622000_97.1.71.26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1994.tb07488.x"},{"key":"2025121202251622000_97.1.71.27","doi-asserted-by":"publisher","DOI":"10.1016\/0022-510X(85)90141-8"},{"key":"2025121202251622000_97.1.71.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70191-6"},{"key":"2025121202251622000_97.1.71.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2017.06.116"},{"key":"2025121202251622000_97.1.71.30","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1093\/brain\/awae048","article-title":"HLA-DQB1*05 subtypes and not DRB1*10:01 mediates risk in anti-IgLON5 disease","volume":"147","author":"Yogeshwar","year":"2024","journal-title":"Brain (Bacau)"},{"key":"2025121202251622000_97.1.71.31","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2020-323226"},{"key":"2025121202251622000_97.1.71.32","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S0165-5728(98)00120-9","article-title":"The impact of HLA on long-term outcome after thymectomy for myasthenia gravis","volume":"88","author":"Machens","year":"1998","journal-title":"J Neuroimmunol"},{"key":"2025121202251622000_97.1.71.33","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/acn3.51309","article-title":"Human Leukocyte Antigen Class II associations in late-onset Myasthenia Gravis","volume":"8","author":"Spagni","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"2025121202251622000_97.1.71.34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/brain\/awn301","article-title":"Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures","volume":"132","author":"Okuda","year":"2009","journal-title":"Brain (Bacau)"},{"key":"2025121202251622000_97.1.71.35","doi-asserted-by":"publisher","DOI":"10.1007\/s004150170205"},{"key":"2025121202251622000_97.1.71.36","doi-asserted-by":"publisher","DOI":"10.1002\/art.34421"},{"key":"2025121202251622000_97.1.71.37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1111\/cei.13302","article-title":"Relation of HLA-DRB1 to IgG4 autoantibody and cytokine production in muscle-specific tyrosine kinase myasthenia gravis (MuSK-MG)","volume":"197","author":"\u00c7ebi","year":"2019","journal-title":"Clin Exp Immunol"},{"key":"2025121202251622000_97.1.71.38","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1376456","article-title":"HLA dependency and possible clinical relevance of intrathecally synthesized anti-IgLON5 IgG4 in anti-IgLON5 disease","volume":"15","author":"Koneczny","year":"2024","journal-title":"Front Immunol"},{"key":"2025121202251622000_97.1.71.39","doi-asserted-by":"publisher","DOI":"10.1111\/ane.13503"},{"key":"2025121202251622000_97.1.71.40","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200179","article-title":"Neuropsychological Testing in Autoimmune Encephalitis: A Scoping Review","volume":"11","author":"Galioto","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Journal of Neurology, Neurosurgery &amp; Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jnnp-2025-335960","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T10:25:49Z","timestamp":1765535149000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnnp.bmj.com\/lookup\/doi\/10.1136\/jnnp-2025-335960"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12,12]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/jnnp-2025-335960"],"URL":"https:\/\/doi.org\/10.1136\/jnnp-2025-335960","relation":{},"ISSN":["0022-3050","1468-330X"],"issn-type":[{"value":"0022-3050","type":"print"},{"value":"1468-330X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]}}}